Drug Resistance in Cancer Cells

Nonfiction, Health & Well Being, Medical, Specialties, Oncology, Medical Science, Pharmacology
Cover of the book Drug Resistance in Cancer Cells by , Springer New York
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9780387894454
Publisher: Springer New York Publication: June 12, 2009
Imprint: Springer Language: English
Author:
ISBN: 9780387894454
Publisher: Springer New York
Publication: June 12, 2009
Imprint: Springer
Language: English

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can be concluded that these patients are dying with drug resistant cancer. The term multidrug resistance is also apt – in that these patients die after having undergone multiple rounds of different and structurally unrelated cancer therapies. However, for some, the concept of m- tidrug resistance is a worn out idea, stemming from disappointment with the drug resistancereversalstrategiesthatwerecarriedoutinthe1990susingpumpinhibitors to block drug resistance mediated by P-glycoprotein, product of the MDR-1 gene. However, if one takes the larger de?nition – multidrug resistance as simultaneous resistance to multiple structurally unrelated anticancer therapies – its existence c- not be denied. The purpose of this book is to explore new concepts related to drug resistance in cancer, including resistance to the new molecularly targeted agents. Perhaps new terminology is needed for resistance that occurs following therapy with the targeted agents: Novel Targeted Agent Resistance (NTR). Alternatively, we can return to the original de?nition of multidrug resistance as simply the res- tance to multipleagents that occurs in the course of normalcancer progression.This resistance is likely to be mediated by many factors.

More books from Springer New York

Cover of the book New Perspectives on Human Sacrifice and Ritual Body Treatments in Ancient Maya Society by
Cover of the book Understanding and Controlling Crime by
Cover of the book Minimally Invasive Cancer Management by
Cover of the book Trade Policy in the Asia-Pacific by
Cover of the book Alcohol and Cancer by
Cover of the book The Political Economy of Regulation in Turkey by
Cover of the book Molecular Neurobiology of Addiction Recovery by
Cover of the book Dynamic-Mismatch Mapping for Digitally-Assisted DACs by
Cover of the book Social Capital and Business Development in High-Technology Clusters by
Cover of the book Neurosociology by
Cover of the book Atherosclerosis Disease Management by
Cover of the book Evolution of Gibbons and Siamang by
Cover of the book Military Deployment and its Consequences for Families by
Cover of the book Converging Disciplines by
Cover of the book Bioinformatics for High Throughput Sequencing by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy